highperformr logo

DayOne Health's Overview

Total employees7
HeadquartersBrisbane
Founded

Day One Biopharmaceuticals (NASDAQ: DAWN), referred to here as DayOne Health for consistency with the request, is a clinical-stage biopharmaceutical company resolutely committed to discovering, developing, and commercializing innovative targeted therapies for patients of all ages afflicted with life-threatening diseases, with an initial focus on pediatric cancers. The company's strategy centers on identifying promising drug candidates that have demonstrated efficacy in adult populations and accelerating their development for pediatric use. Their flagship product candidate, OJEMDA™ (tovorafenib, formerly DAY101), is an oral, brain-penetrant, highly selective type II PAN-RAF kinase inhibitor. Day One is propelled by a profound mission: to deliver transformative medicines to those patients who are most in need.

Where is DayOne Health's Headquarters?

HQ Function

The headquarters serves as the central hub for corporate operations, clinical development leadership, research activities, and strategic planning for Day One Biopharmaceuticals' global initiatives.

Notable Features:

Situated within a modern biotechnology campus in the San Francisco Bay Area, the headquarters likely features advanced laboratory and office facilities conducive to biopharmaceutical research and development.

Work Culture:

Day One Biopharmaceuticals fosters a dynamic, science-driven, and mission-focused work environment. The culture emphasizes collaboration, innovation, and a sense of urgency, reflecting its commitment to addressing critical needs in oncology, particularly for pediatric patients.

HQ Significance:

The Brisbane headquarters is strategically positioned within one of the world's foremost biotechnology clusters, providing Day One with access to a rich ecosystem of talent, leading research institutions, and investment opportunities.

Values Reflected in HQ: The headquarters' design and functionality are expected to mirror Day One's core values of scientific excellence, innovation, patient-centricity, and collaborative teamwork, creating an environment that supports their mission.

Location:

While Day One Biopharmaceuticals is headquartered in the United States, its operational footprint is global, particularly concerning its clinical development programs. The company conducts international clinical trials, such as the pivotal FIREFLY-1 study for tovorafenib, across multiple countries in North America, Europe, and Asia-Pacific. This global approach is essential for accessing diverse patient populations, especially in rare pediatric cancers, and for gathering comprehensive data to support regulatory submissions worldwide. Future commercialization strategies for approved therapies like OJEMDA™ are also expected to encompass key international markets.

Street Address:

5000 Marina Boulevard, Suite 300

City:

Brisbane

State/Province:

CA

Country:

USA

DayOne Health's Global Presence

Primarily Centralized Operations

Address: N/A

The focus on a central headquarters supports streamlined R&D, clinical operations management, and corporate functions, while global clinical trials ensure broad patient access and data collection.

Buying Intent Signals for DayOne Health

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of DayOne Health

As of April 2025, DayOne Health' leadership includes:

Jeremy Bender, Ph.D. - Chief Executive Officer
Samuel Blackman, M.D., Ph.D. - Co-Founder, Head of Research and Development
Charles N. York II - Chief Operating Officer & Chief Financial Officer
Lauren Merendino - Chief Commercial Officer
Raphaël Rousseau, M.D., Ph.D. - Chief Medical Officer
Scott F. Smith - Chief People Officer
Neha Krishnamohan - Chief Business Officer
Daven Kono, M.D. - Chief Medical Affairs Officer

Investors of DayOne Health

DayOne Health has been backed by several prominent investors over the years, including:

RA Capital Management
Boxer Capital
Canaan Partners
Access Biotechnology
Atlas Venture
OrbiMed
Fidelity Management & Research Company
Franklin Templeton
Perceptive Advisors
Logos Capital

Executive New Hires/Exits in the Last 12 Months

Hire3
Exits0

Over the past 12 months, Day One Biopharmaceuticals has significantly strengthened its executive leadership team with strategic appointments to key C-suite positions, including Chief People Officer, Chief Business Officer, and Chief Medical Affairs Officer, to support its continued growth and the commercialization of its therapies. No major C-level departures were publicly announced during this period.

New Appointments:

Scott F. Smith, Scott F. Smith appointed as new Chief People Officer.
Neha Krishnamohan, Neha Krishnamohan appointed as new Chief Business Officer.
Daven Kono, M.D., Daven Kono, M.D. appointed as new Chief Medical Affairs Officer.

Technology (Tech Stack) used by DayOne Health

Discover the tools DayOne Health uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

DayOne Health Email Formats and Examples

Day One Biopharmaceuticals likely utilizes standard corporate email address formats. The most common patterns for companies of this type include combinations of the employee's first name, last name, or initials with the company domain.

[first_initial][last]@dayonebio.com

Format

jsmith@dayonebio.com

Example

75%

Success rate

News and media

Day One Biopharmaceuticals / GlobeNewswireApril 23, 2024

DayOne Health (Day One Biopharmaceuticals) Announces U.S. FDA Accelerated Approval of OJEMDA™ (tovorafenib) for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma (pLGG)

Day One Biopharmaceuticals received landmark U.S. FDA accelerated approval for OJEMDA™ (tovorafenib). This novel therapy is indicated for patients aged 6 months and older who have relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation. This approval represents a major advancement for children with this common type of brain tumor....more

Day One Biopharmaceuticals / GlobeNewswireMay 9, 2024

DayOne Health (Day One Biopharmaceuticals) Reports First Quarter 2024 Financial Results and Provides Corporate Update

Day One Biopharmaceuticals announced its financial results for the first quarter of 2024, highlighting $0.7 million in initial net product revenue from OJEMDA™ sales following its FDA approval. The company also provided updates on its commercial launch activities and ongoing clinical development pipeline, emphasizing its strong financial position to support future growth....more

Day One Biopharmaceuticals / GlobeNewswireJanuary 3, 2024

DayOne Health (Day One Biopharmaceuticals) Appoints Daven Kono, M.D. as Chief Medical Affairs Officer

Day One Biopharmaceuticals announced the appointment of Daven Kono, M.D., as Chief Medical Affairs Officer. Dr. Kono brings over 15 years of experience in global medical affairs and will lead the company's medical affairs strategy and operations to support the launch and lifecycle management of its therapies....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including DayOne Health, are just a search away.